A study found in Obesity Reviews showed that phosphodiesterase 4 (PDE4) inhibition could be useful in the treatment of metabolic disorders. Researchers discovered that signaling disruptions between cyclic adenosine monophosphate and PDE4 represented a meaningful pathway for metabolic diseases.
A few PDE4 inhibitors are currently going through clinical evaluation to treat some metabolic disorders, including non-alcoholic steatohepatitis and type 2 diabetes. The discovery of PDE4 allosteric inhibitors along with strategies that target individual PDE4 variants could allow for PDE4 isoform selective inhibition. This could potentially offer safe strategies when it comes to the treatment of chronic metabolic disorders.
These findings were published in Obesity Reviews on March 21, 2016.